Transplatin-modified oligonucleotides as modulators of gene expression

Pharmacology and Therapeutics

Volumn 85, Issue 3, 2000, Pages 175-181

  Giraud Panis, Marie Josèphe ^a   Leng, Marc ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

Antisense strategy; Interstrand cross links; Oligonucleotides; Transplatin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; PLATINUM DERIVATIVE; TRANSPLATIN;

CONFERENCE PAPER; CROSS LINKING; DNA ADDUCT; DRUG SYNTHESIS; GENE EXPRESSION; ISOMERISM; PRIORITY JOURNAL;

BINDING SITES; CISPLATIN; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDES;

EID: 0034021505     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00058-3     Document Type: Conference Paper

References (42)

1. Agrawal S. Antisense oligonucleotides. towards clinical trials Trends Biotechnol. 14:1996;376-387.
2. Anin M.F., Leng M. Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diamminedichloroplatinum(II) to the d(GTG) sequence. Nucleic Acids Res. 18:1990;4395-4400.
3. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc. 112:1990;6860-6871.
4. Bernal-Mendez E., Boudvillain M., Gonzalez-Vilchez F., Leng M. Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA. Biochemistry. 36:1997;7281-7287.
5. Boccarelli A., Coluccia M., Intini F.P., Natile G., Locker D., Leng M. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands. Anticancer Drug Des. 4:1999;253-264.
6. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
7. Boudvillain M., Dalbiès R., Aussourd C., Leng M. Intrastrand crosslinks are not formed in the reaction between transplatin and native DNA. relation with the clinical inefficiency of transplatin Nucleic Acids Res. 23:1995;2381-2388.
8. Boudvillain M., Guerin M., Dalbies R., Saison-Behmoaras T., Leng M. Transplatin-modified oligo(2′-O-methyl ribonucleotide)s. a new tool for selective modulation of gene expression Biochemistry. 36:1997;2925-2931.
9. Brabec V., Leng M. Interstrand crosslinks of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA. 90:1993;5345-5349.
10. 2]. Nucleic Acids Res. 24:1996;336-341.
11. Chadwick, D. J., & Cardew, G. (1997). Oligonucleotides as Therapeutic Agents, Ciba Foundation Symposium 209. Chichester: Wiley.
12. Comess K.M., Costello C.E., Lippard S.J. Identification and characterization of a novel linkage isomerization in the reaction of trans-diamminedichloroplatinum(II) with 5′-d(TCTACGCGTTCT). Biochemistry. 29:1990;2102-2110.
13. Dalbies R., Payet D., Leng M. DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)-modified DNA. Proc Natl Acad Sci USA. 91:1994;8147-8151.
14. Dalbies R., Boudvillain M., Leng M. Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum(II)-modified single-stranded oligonucleotides. Nucleic Acids Res. 23:1995;949-953.
15. de Lange T., Jacks T. For better and worse? Telomerase inhibition and cancer. Cell. 98:1999;273-275.
16. Eastman A., Barry M. Interaction of trans-diamminedichloroplatinum(II) with DNA. formation of monofunctional adducts and their reaction with glutathione Biochemistry. 26:1987;3303-3307.
17. Eastman A., Jennerwein M.M., Nagel D.L. Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II). Chem Biol Interact. 67:1988;71-80.
18. Gaucheron F., Malinge J.M., Blacker A.J., Lehn J.M., Leng M. Possible catalytic activity of DNA in the reaction between the antitumor drug cis-diamminedichloroplatinum(II) and the intercalator N-methyl-2,7-diazapyrenium. Proc Natl Acad Sci USA. 88:1991;3516-3519.
19. Giovannangeli C., Hélène C. Progress in developments of triplex-based strategies. Antisense Nucleic Acid Drug Dev. 7:1997;413-421.
20. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., De Lange T. Mammalian telomeres end in a large duplex loop. Cell. 97:1999;503-514.
21. Guo Z., Sadler P. Metals in medicine. Angew Chem Int Ed. 38:1999;1513-1531.
22. Hahn W., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
23. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol. 6:1999;343-351.
24. + J Med Chem. 32:1989;128-136.
25. Legendre F., Chottard J.C. Kinetics and selectivity of DNA-platination. Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;224-245 Verlag Helvetica Chimica Acta, Zurich.
26. Lepre C.A., Lippard S.J. Interaction of platinum compounds with DNA. Eckstein F., Lilley D.M.J. Nucleic Acids and Molecular Biology, Vol. 4. 1990;9-38 Springer-Verlag, Berlin, Heidelberg, and New York.
27. Lippert B., Leng M. Role of metal ions in antisense and antigene strategies. Clarke M.J., Sadler P.J. Topics in Biological Inorganic Chemistry, Vol. 1. 1999;118-142 Springer-Verlag, Berlin, Heidelberg, and New York.
28. Malinge J.M., Leng M. Interstrand cross-links in cisplatin- or transplatin-modified DNA. Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;159-180 Verlag Helvetica Chimica Acta, Zurich.
29. Martin R.B. Platinum complexes. hydrolysis and binding to N(7) and N(1) of purines Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;183-205 Verlag Helvetica Chimica Acta, Zurich.
30. Natile G., Coluccia M. trans-Platinum compounds in cancer therapy. a largely unexplored strategy for identifying novel antitumor platinum drugs Clarke M.J., Sadler P.J. Topics in Biological Inorganic Chemistry, Vol. 1. 1999;74-115 Springer-Verlag, Berlin, Heidelberg, and New York.
31. O'Dwyer P.J., Stevenson J.A., Johnson S.W. Clinical status of cisplatin, carboplatin and other platinum-based drugs. Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;31-69 Verlag Helvetica Chimica Acta, Zurich.
32. O'Reilly M., Teichmann S.A., Rhodes D. Telomerases. Curr Opin Struct Biol. 9:1999;56-65.
33. Paquet F., Boudvillain M., Lancelot G., Leng M. NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7/CN3 cross-link. Nucleic Acids Res. 27:1999;4261-4268.
34. Pérez C., Leng M., Malinge J.M. Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res. 25:1997;896-903.
35. Pitts A.E., Corey D.R. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci USA. 95:1998;11549-11554.
36. Reedijk J., Teuben J.M. Platinum-sulfur interactions involved in antitumor drugs, rescue agents and biomolecules. Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;339-362 Verlag Helvetica Chimica Acta, Zurich.
37. Sierakowska H., Sambade M.J., Agrawal S., Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA. 93:1996;12840-12844.
38. Wagner R.W., Flanagan W.M. Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today. 3:1997;31-38.
39. Yang D., Wang A.H.J. Structural studies of interactions between anticancer platinum drugs and DNA. Prog Biophys Mol Biol. 66:1996;81-111.
40. Yang D., van Boom S.S.G.E., Reedijk J., van Boom J.H., Wang A.H.J. Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry. 34:1995;12912-12920.
41. 2]. Mol Pharmacol. 52:1997;354-361.
42. Zamble D.B., Lippard S.J. The response of cellular proteins to cisplatin-damaged DNA. Lippert B. Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;74-110 Verlag Helvetica Chimica Acta, Zurich.